Guangxi Wuzhou Zhongheng Group Co., Ltd.SSE: 600252

(600252)"Guangxi Wuzhou Zhongheng Group Co., Ltd."Announcement on Proposed Public Listing for Sale of Certain Assets by the Controlled Subsidiary Lummy Pharmaceutical

· Issued by Guangxi Wuzhou Zhongheng Group Co., Ltd. via Shanghai Stock Exchange

Filed with SSE · Stock code 600252 · · 8 pages · Chinese

Summary by 6ix AI

Guangxi Wuzhou Zhongheng Group Co., Ltd. announced plans for its controlled subsidiary, Lummy Pharmaceutical, to publicly list certain assets for sale, including land use rights and buildings in Chongqing. The initial listing price for these assets will be based on an assessment value, with the final transaction amount to be determined through public bidding. The board has approved this transaction, which does not constitute a major asset restructuring and is expected to enhance the subsidiary's operational efficiency. The sale is subject to public listing procedures, and the company will provide updates on the transaction's progress as necessary.

Written in English by 6ix AI from the company’s Chinese-language filing. How 6ix writes summaries

On 6ix: 6ix.com/news/600252guangxi-wuzhou-zhongheng-group-co-ltdannouncement-on-proposed-public-listing-for-sale-of-certain-assets-by-the-controlled-subsidiary-lummy-pharmaceutical

Release

Announcement on Proposed Public Listing for Sale of Certain Assets by the Controlled Subsidiary Lummy Pharmaceutical

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference:

Guangxi Wuzhou Zhongheng Group Co., Ltd. on 6ix

Story so far

Earlier from Guangxi Wuzhou Zhongheng

All Guangxi Wuzhou Zhongheng news releases